Aaron Hieb
Research Subjects
Aaron Hieb has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Adam Palmer Rauk
Development Statistics, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN 46225, USA
1 shared publicationAmy St. Charles
Pfizer, Inc., Analytical Research & Development, 875 Chesterfield Parkway West, Chesterfield, MO 63017, USA
1 shared publicationAndrea Ji
Genentech, Pharmaceutical Development, 1 DNA Way, South San Francisco, CA 94080
1 shared publicationArmin Boehrer
Boehringer Ingelheim Pharma GmbH & Co. KG, Global Development CMC Biologicals, 88397 Biberach/Riss, Germany
1 shared publicationArthur J. Schick
Protein Analytical Chemistry, Genentech, South San Francisco, CA, 94080, USA
1 shared publicationBen Ahlstrom
Amgen Inc., Quality, One Amgen Center Drive, Thousand Oaks, CA 91320
1 shared publication
Latest Publications
- Open Access
- 13 June 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (8) , 103873
Predictive stability in biopharmaceuticals and vaccines: Perspectives and recommendations towards accelerating patient access
- 13 June 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (8) , 103873
Open AccessPredictive stability in biopharmaceuticals and vaccines: Perspectives and recommendations towards accelerating patient access
- Open Access
- 2 May 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 1326-1334
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulation of ranibizumab, and four dedicated ancillary devices for initial fill, surgical implantation, refill-exchange, and explantation, if clinically indicated. Ranibizumab is an ideal candidate for the PDS on account of its unique physicochemical stability and high solubility. Controlled release is achieved via passive diffusion through the porous release control element, which is tuned to specific drug characteristics to accomplish a therapeutic level of ranibizumab in the vitreous. To characterize drug release from the implant, release rate was measured in vitro with starting concentrations of ranibizumab 10, 40, and 100 mg/mL, with release of ranibizumab 40 and 100 mg/mL found to remain quantifiable after 6 months. Using a starting concentration of 100 mg/mL, active release rate at approximately 6 months was consistent after the initial fill and first, second, and third refills, demonstrating reproducibility between implants and between multiple refill-exchanges of the same implant. A refill-exchange performed with a single 100-µL stroke using the refill needle was shown to replace over 95% of the implant contents with fresh drug. In vitro data support the use of the PDS with fixed refill-exchange intervals of at least 6 months in clinical trials.
- 2 May 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 1326-1334
Open AccessThe Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulation of ranibizumab, and four dedicated ancillary devices for initial fill, surgical implantation, refill-exchange, and explantation, if clinically indicated. Ranibizumab is an ideal candidate for the PDS on account of its unique physicochemical stability and high solubility. Controlled release is achieved via passive diffusion through the porous release control element, which is tuned to specific drug characteristics to accomplish a therapeutic level of ranibizumab in the vitreous. To characterize drug release from the implant, release rate was measured in vitro with starting concentrations of ranibizumab 10, 40, and 100 mg/mL, with release of ranibizumab 40 and 100 mg/mL found to remain quantifiable after 6 months. Using a starting concentration of 100 mg/mL, active release rate at approximately 6 months was consistent after the initial fill and first, second, and third refills, demonstrating reproducibility between implants and between multiple refill-exchanges of the same implant. A refill-exchange performed with a single 100-µL stroke using the refill needle was shown to replace over 95% of the implant contents with fresh drug. In vitro data support the use of the PDS with fixed refill-exchange intervals of at least 6 months in clinical trials.
- 1 November 2020
- Published by Elsevier in Analytical Biochemistry
- Vol. 609, 113948
Using differential scanning calorimetry for the development of non-reduced capillary electrophoresis sodium dodecyl sulfate methods for monoclonal antibodies
- 1 November 2020
- Published by Elsevier in Analytical Biochemistry
- Vol. 609, 113948
Using differential scanning calorimetry for the development of non-reduced capillary electrophoresis sodium dodecyl sulfate methods for monoclonal antibodies